TICKERNERD
Menu
NRXPNRXPHealthcare · Biotechnology

NRXP Stock Forecast: NRX Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.89
−0.34% on the day

The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. hold a median 12-month price target of $47 — +1526.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$125.6M
Ticker Nerd rank
18 / 100
Median analyst target
$47
Analysts covering
4
Revenue$1.1M
Operating income−$6.5M
Net income−$16.5M
Free cash flow−$9.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
−16.7%
YTD
+6.6%
1Y
−19.3%
From 52W high
−37.4%
From 52W low
+72.0%
$1.68
$4.62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NRXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NRX Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Issuance
60
Momentum
60
Growth
43
Accruals
31
Revisions
27
Volatility
16
Value
8
Quality
6

Size (73): Smaller than most of the companies we track.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00Jan 26Apr 26Jul 26Oct 26NRXPHigh $50Median $47Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $10Median $47High $50

The green dot is the last close — the median target sits +1526.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Oct 2026Ascendiant CapitalMaintainsBuy$49 → $50
14 Sept 2026BTIGReiteratesBuy—
14 Sept 2026BTIGReiteratesBuy$10
25 Aug 2026HC Wainwright & Co.ReiteratesBuy—
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$45
18 Aug 2026BTIGReiteratesBuy$10
18 Aug 2026BTIGReiteratesBuy—
7 Aug 2026BTIGMaintainsBuy—
7 Aug 2026BTIGMaintainsBuy$25 → $10
5 May 2026D. Boral CapitalMaintainsBuy—
5 May 2026D. Boral CapitalMaintainsBuy$34
27 Apr 2026Ascendiant CapitalMaintainsBuy—
27 Apr 2026HC Wainwright & Co.ReiteratesBuy—
23 Apr 2026D. Boral CapitalMaintainsBuy—
20 Apr 2026D. Boral CapitalMaintainsBuy—
24 Mar 2026BTIGReiteratesBuy—
24 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NRXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, NRX Pharmaceuticals, Inc. returned −19.3% against +16.2% for the S&P 500, dividends included.

NRXP vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26NRXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NRXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

NRX Pharmaceuticals, Inc. (NRXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.4×

Cheaper than 72% of US stocks

Price / sales
37.0×

Cheaper than 6% of US stocks

Price / book
−642.3×

Cheaper than 99% of US stocks

EV / EBITDA
−5.1×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
3.1%

Higher than 35% of US stocks

Earnings growth (YoY)
—
Gross margin
38.7%

Higher than 47% of US stocks

Operating margin
−590.5%

Higher than 7% of US stocks

Net margin
58.8%

Higher than 97% of US stocks

Returns & dividend
Return on equity
179.6%

Higher than 98% of US stocks

Return on assets
−64.0%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NRX Pharmaceuticals, Inc. (NRXP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NRX Pharmaceuticals, Inc. has a market value of $125.6M and an enterprise value of $101.3M.

  • Revenue in the twelve months to 30 June 2026: $3.4M. The latest quarter grew 3.1% year on year.

  • Net income over the same four quarters: −$23.5M, a −691.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.7M.

  • Shares outstanding: 43.2M.

  • Trailing P/E: 0.4×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • NRX Pharmaceuticals, Inc. employs 29 people — $117K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

NRXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRXPNRX Pharmaceuticals, Inc.$125.6M
18
CBUSCibus, Inc.$121.1M
42
HUMAHumacyte, Inc.$120.6M
18
SEERSeer, Inc. (California)$122.1M
75
VTVTvTv Therapeutics, Inc.$118.5M
77
TNYATenaya Therapeutics, Inc.$117.8M
32
TNXPTonix Pharmaceuticals Holding Corp.$124.9M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NRX Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRXP news & analysis

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

GlobeNewsWire · 30 Sept 2026positive

NRx Defense Systems, an NRx company trading on Nasdaq under NRXP, was awarded an $11 million DARPA prime contract to evaluate robotic magnetic stimulation in combination with NRX-101 for the treatment of resistant depression. DARPA noted the program could fundamentally change the standard of care for treatment-resistant depression, as current treatments are not deployable in operational military settings.

Why it matters — A NRXP watcher would care because this government contract provides funding and official recognition for the company's NRX-101 program in the treatment-resistant depression space.

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

GlobeNewsWire · 15 Sept 2026positive

NRx Pharmaceuticals announced it received written communication from the FDA Office of Generic Drugs that the amendment to its Abbreviated New Drug Application for preservative-free ketamine, previously classified as a Major Amendment, has been reclassified as a Minor Amendment.

Why it matters — A reclassification from a Major to a Minor amendment typically signals a less burdensome review process for the ANDA, which NRx watchers may see as a favorable development for the company's regulatory timeline.

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry

Seeking Alpha · 14 Sept 2026positive

Seeking Alpha highlights KETAFREE as a promising commercial opportunity for NRx Pharmaceuticals in the psychiatric ketamine space, contingent on FDA approval and a successful launch. The article notes that NRXP's HOPE program provides clinical infrastructure, though it currently contributes a relatively small revenue base.

Why it matters — NRXP watchers would care because the company's bull case hinges on successfully commercializing KETAFREE, building on the clinical infrastructure provided by its HOPE program.

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

GlobeNewsWire · 14 Sept 2026positive

GeNeuro, Inc., an NRx company trading as Nasdaq:NRXP, has been awarded European Patent Rights for GNK-301, a novel drug candidate intended to treat Amyotrophic Lateral Sclerosis (ALS). The patent is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein, which is found in the spinal fluid of more than 75% of people with ALS and has been shown to produce neurodegenerative ALS findings in experimental systems.

Why it matters — NRXP watchers would take note because patent protection secured in Europe for the GNK-301 ALS candidate expands and strengthens the company's intellectual property for a novel therapy targeting a potentially root-cause mechanism of ALS.

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

GlobeNewsWire · 11 Sept 2026positive

NRx Pharmaceuticals announced that its subsidiary HOPE Therapeutics will be the first Interventional Psychiatry practice to deploy Zeta Surgical's newly FDA-cleared Zeta TMS Robotic System, with clinical staff now in training ahead of deployment in Florida.

Why it matters — This positions HOPE Therapeutics at the forefront of deploying a newly FDA-cleared robotic TMS system, which expands the company's clinical capabilities and service offerings.

FAQ

Frequently asked questions about NRXP stock

What is the NRXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. have a median 12-month price target of $47, with estimates ranging from $10 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRXP stock a buy right now?

Of the 4 analysts covering NRX Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NRX Pharmaceuticals, Inc. 18 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRXP?

As at 8 Oct 2026, NRX Pharmaceuticals, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will NRXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +1526.3% from the last close, and Ticker Nerd's factor model ranks NRX Pharmaceuticals, Inc. 18 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRXP stock forecast for 2030?

No analyst covering NRX Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $50 over the next 12 months.

How has NRXP stock performed over the past year?

NRX Pharmaceuticals, Inc. returned -19.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NRX Pharmaceuticals, Inc. do?

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation.

What is the latest news on NRXP?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression". NRx Defense Systems, an NRx company trading on Nasdaq under NRXP, was awarded an $11 million DARPA prime contract to evaluate robotic magnetic stimulation in combination with NRX-101 for the treatment of resistant depression. DARPA noted the program could fundamentally change the standard of care for treatment-resistant depression, as current treatments are not deployable in operational military settings.

Company

About NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation. Its current pipeline centers on NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. The company also works on adjacent neuropsychiatric and respiratory care initiatives through its broader portfolio and operating segments. NRx Pharmaceuticals, Inc. serves a specialized role in psychiatry by targeting high-unmet-need conditions where conventional treatment options may be limited or insufficient. Headquartered in Wilmington, Delaware, it operates as a focused developer of novel therapeutics for complex mental health and neurological indications.

CEO Dr. Jonathan C. Javitt M.D., M.P.H. · 29 employees · United States · https://www.nrxpharma.com